invention may be administered in a manner appropriate to the disease to be treated or prevented appropriate dosages and a suitable duration and frequency of administration may be determined by such factors as the condition of the patient the type and severity of the patient 39 s disease and the method of administration in general an appropriate dosage and treatment regimen provides the compound s in an amount sufficient to provide treatment and or prophylactic benefit within particularly preferred embodiments of the invention a compound may be administered in a composition of the present invention at a dosage ranging from 0 001 to 1000 mg kg body weight more typically 0 01 to 1000 mg kg on a regimen of single or multiple daily doses appropriate dosages may generally be determined using experimental models and or clinical trials in general the use of the minimum dosage that is sufficient to provide effective therapy is preferred patients may generally be monitored for therapeutic effectiveness using assays suitable for the condition being treated or prevented which will be familiar to those of ordinary skill in the art compounds as set forth above may also be used to target substances to pseudomonas bacteria e g p aeruginosa such substances include therapeutic agents and.